| 产品描述: | Cimpuciclib tosylate is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity. |
| 靶点: |
CDK4:0.49 nM (IC50);CDK6:9.56 nM (IC50) |
| 体外研究: |
Cimpuciclib (example 63, 50 mg/kg, oral gavage, twice a week) tosylate inhibits tumor growth in colo205 tumor-bearing mice[1]. Cimpuciclib (5 mg/kg for rats, 50 mg/kg for colo205 tumor-bearing mice, oral administration) tosylate shows slow metabolic rate and maintains high concentration in the plasma[1]. |
| 体内研究: |
Cimpuciclib (example 63, 141.2 nM, 6 days) tosylate inhibits proliferation of colo205 cells. |
| 参考文献: |
1. Liu Shiqiang, et al. Preparation of benzimidazole compound as kinase inhibitor. Patent WO 2018045956. |
| 保存条件: |
2-8°C, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.399 ml |
6.994 ml |
13.989 ml |
| 5 mM |
0.28 ml |
1.399 ml |
2.798 ml |
| 10 mM |
0.14 ml |
0.699 ml |
1.399 ml |
| 50 mM |
0.028 ml |
0.14 ml |
0.28 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |